Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF for ocular surface regeneration in chronically treated glaucoma patients
2019-001647-46Phase 2Active
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Nov 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of factor-rich plasma in Glaucoma and ocular surface disease (OSD), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Tear osmolarity. Started Nov 2019; status: active.
02
Drugs
factor-rich plasma
03
Conditions
Glaucomaocular surface disease (OSD)
Beyond the preview
Go deeper on 2019-001647-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001647-46.